Abnormalities of cerebral blood flow and the regional brain function in Parkinson’s disease: a systematic review and multimodal neuroimaging meta-analysis Authors: Hao Xie, Yang Yang, Qian Sun, Ze-Yang Li, Min-Hua Ni, Zhu-Hong Chen, Si-Ning Li, Pan Dai, Yan-Yan Cui, Xin-Yu Cao, Nan Jiang, Li-Juan Du, Ying Yu, Lin-Feng Yan, Guang-Bin Cui Published: 2023 ABSTRACT BackgroundParkinson’s disease (PD) is a neurodegenerative disease with high incidence rate. Resting state functional magnetic resonance imaging (rs-fMRI), as a widely used method for studying neurodegenerative diseases, has not yet been combined with two important indicators, amplitude low-frequency fluctuation (ALFF) and cerebral blood flow (CBF), for standardized analysis of PD.MethodsIn this study, we used seed-based d-mapping and permutation of subject images (SDM-PSI) software to investigate the changes in ALFF and CBF of PD patients. After obtaining the regions of PD with changes in ALFF or CBF, we conducted a multimodal analysis to identify brain regions where ALFF and CBF changed together or could not synchronize.ResultsThe final study included 31 eligible trials with 37 data sets. The main analysis results showed that the ALFF of the left striatum and left anterior thalamic projection decreased in PD patients, while the CBF of the right superior frontal gyrus decreased. However, the results of multimodal analysis suggested that there were no statistically significant brain regions. In addition, the decrease of ALFF in the left striatum and the decrease of CBF in the right superior frontal gyrus was correlated with the decrease in clinical cognitive scores.ConclusionPD patients had a series of spontaneous brain activity abnormalities, mainly involving brain regions related to the striatum-thalamic-cortex circuit, and related to the clinical manifestations of PD. Among them, the left striatum and right superior frontal gyrus are more closely related to cognition.Systematic review registrationhttps://www.crd.york.ac.uk/ PROSPERO (CRD42023390914). Introduction Parkinson’s disease (PD) is a neurodegenerative disease with the pathological characteristics of loss of dopamine neurons and aggregation of Lewy bodies (1). In the United States, Parkinson’s disease affects almost six per 1,000 people age 45 and over (2), and the incidence rate of Parkinson’s disease is increasing in most countries in the world (3, 4). Due to the increase in disease awareness, aging population, and environmental changes, the number of PD patients continues to increase, which has become a public health issue in aging societies across countries (5). The clinical manifestations of PD are divided into motor symptoms and non-motor symptoms. Motor symptoms include common symptoms such as tremor, bradykinesia, rigidity and gait disorders. With the deepening of research in recent years, cognitive disorders, sleep disorders, mood changes and other non-motor symptoms have gradually become the focus (6, 7). Especially cognitive impairment, which can lead to dementia, seriously affect patients’ health and increase social burden (8). Therefore, a better understanding of the neural substrates of cognitive impairment in PD is urgently required to direct effective and targeted treatment strategies. In previous studies, researchers have tried many methods to clarify the physiological basis of PD, such as animal experiments, single photon emission computed tomography (SPECT) and resting state fMRI functional magnetic resonance imaging (rs-fMRI) (9, 10). Among them, rs-fMRI has been widely used in PD and other degenerative disease due to its advantages of non-invasive, efficient, and high spatial resolution imaging mode that can reflect the activities of the central nervous system. Amplitude of low-frequency fluctuations (ALFF) is an important indicator of rs-fMRI, obtained by measuring blood oxygen level dependent (BOLD) signals (11). Cerebral blood flow (CBF) is another important indicator obtained by measuring magnetic labeled endogenous arterial blood as a tracer using arterial spin labeling (ASL) technology (12, 13). The individual ALFF and CBF represent the neural activity and blood flow perfusion of the local brain region, respectively, and both indicators also reflect the intensity of neural activity in the brain region through direct and indirect means (14, 15). In addition, combining two indicators of the same brain region can reflect the neurovascular coupling state of a certain region (16, 17). Therefore, it is crucial to conduct research and analysis on these two indicators. Previous researchers have conducted years of research on PD based on ALFF and CBF, and have published many research results. However, due to differences in sample size, demographic information, ethnic distribution (many studies on East Asian populations), and clinical data, there may be significant heterogeneity and bias among studies. Some researchers have attempted to integrate the results using meta-analysis and review. For example, previous ALFF meta-analysis results have shown that PD patients have a decrease in ALFF in areas such as the left superior temporal gyrus and left superior frontal gyrus, while an increase in ALFF in areas such as the right superior frontal gyrus and left superior parietal lobule (18). The retrospective analysis of brain perfusion in PD patients using the ASL technique in the past suggests that the main brain regions related to motor and non-motor symptoms of PD, such as the basal ganglia subregion, frontoparietal network, and visual network, have been identified as insufficient CBF perfusion (19). The above results have significant differences and high heterogeneity due to differences in inclusion criteria and specific analysis methods in the literature. Therefore, it is essential to explore the brain regions affected by ALFF and CBF in PD using consistent methods and a more comprehensive analysis process. Based on this, we conducted this study. The purpose of this study is to conduct multimodal meta-analysis of the changes of ALFF and CBF in PD compared with normal controls through whole-brain meta-analysis technology, and explore areas of the brain where ALFF, CBF, or both have changed, providing neuroimaging evidence for the clinical manifestations of PD, and attempting to identify neuroimaging biomarkers that lead to cognitive impairment, in order to assist in the early diagnosis and intervention of such patients. Methods Search strategy The study followed the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and 10 simple rules for neuroimaging meta-analysis (20, 21). The protocol was registered in PROSPERO (CRD42023390914).1 Two databases were searched including PubMed, Web of Science, from Jan 1, 2007 to Dec 1, 2022. Based on the two indicators of ALFF and CBF, this search was divided into two parts. The first part used keywords: (“Parkinson’s Disease” OR “Parkinson Disease” OR “Parkinsonism” OR “Paralysis Agitans” OR “PD”) AND (“amplitude of low frequency fluctuation” OR “ALFF” OR “low frequency fluctuation” OR “LFF” OR “amplitude of low frequency oscillation” OR “LFO”). The second part used keywords: (“Parkinson’s Disease” OR “Parkinson Disease” OR “Parkinsonism” OR “Paralysis Agitans” OR “PD”) AND (“Cerebrovascular Circulation” OR “arterial spin labeling” OR “ASL” OR “Cerebral Blood Flow” OR “CBF”). Study selection After searching for studies, we first excluded duplicate studies. When reading and extracting information from the entire text, if there was any information not mentioned in the original text, such as coordinate values, non-online manuscripts, etc., the corresponding author would be contacted by email. Extracting information and conducting research, studies conforming to the following criteria were included: (1) the exploration of ALFF or CBF alterations between PD patients and healthy controls (HCs); (2) the subjects are adults; (3) PD patients were in an off-state; (4) the article clearly depicted the peak coordinates (Talairach or MNI) in the three-dimensional stereo directional coordinates; (4) available t values, p value or z values are provided in the study; (5) original research published in peer-reviewed journals. Studies conforming to the following criteria were excluded: (1) no HCs; (2) subjects with other diseases of central system or affecting brain activity; (3) animal study; (4) not related to ALFF and CBF; (5) studies with ROI analysis (6) research on minors; (7) secondary study; (8) neuroimaging quality score<16 or JBI score<12. Quality assessment We formulated the quality assessment method of this study referring to the previous high-quality research (22). Based on this, we used the checklist for objective evaluation of the quality of the neuroimaging meta-analysis research method (Supplementary Figure S1). In addition, the Joanna Briggs Institute (JBI) critical appraisal checklist (Supplementary Table S4) by the cross-sectional study was also used to conduct a secondary assessment of the quality of the included studies (23). Two reviewers (H.X and ZY.L, Radiologist) independently evaluated the quality of the article. If any differences were encountered during the process, the third reviewer (LF.Y, Deputy Chief Radiologist and Associate Professor) would make the final decision. Voxel-wise meta-analysis of CBF and ALFF abnormalities In this study, we used the SDM-PSI software (version 6.212) to analyze studies on ALFF and CBF separately. SDM-PSI is a voxel based meta-analysis software that recreates brain maps comparing the effectiveness of results by using peak coordinates reported in research results and statistical effects extracted from each original study. The specific analysis process was reported in detail in previous articles (23–26). The main processes were briefly summarized: (1) global analysis; (2) pre-processing; (3) mean analysis; (4) threshold analysis; (5) family-wise error (FWE) correction; (6) threshold analysis and (7) extract peak coordinates and bias test. Finally, we used MICRON3 software to visualize the data results. The parameters used in this analysis were p < 0.005 uncorrected, minimum cluster extension>10 voxels and SDM-Z > 1 (which can reduce the possibility of false positive) (25). These parameters were recommended by the software developer and can best balance false positive and false results to obtain the best results (21, 25). Heterogeneity, sensitivity and publication bias In this study, we used Stata software to evaluate the heterogeneity of the results and conducted statistical analysis by extracting the peak coordinates of meaningful results. The results of the I2 statistic were used to evaluate the heterogeneity between studies. I2<50% usually indicates a low heterogeneity of the results (27). In order to determine whether there was potential publication bias, we conducted Egger’s test and drew a funnel map for visual inspection. Asymmetric funnel map or Egger’s test result p < 0.05 indicated that there was significant publication bias (28). The sensitivity analysis based on whole-brain voxel used AES-SDM software to test the reliability of the results by eliminating one data set at a time and then performing the same analysis method (22, 29). If a region was significant in most data set combinations (>50%), the result was considered highly reproducible and trustworthy. Multimodal analysis of ALFF and CBF Areas of shared abnormalities between patient groups versus control subjects of ALFF and CBF were determined in conjunction analyses by computing p value overlap within each voxel from the original meta-analytic maps accounting for error. Conjunction analysis determined overlapping (or distinct) regions between patient groups across both modalities. Meta-regression analysis Meta-regressions were conducted within the PD group to examine effects of age, course of disease, and clinical scale results on ALFF and CBF abnormalities. In order to minimize the false correlation, we adopted a low probability threshold of 0.0005. We ignored the results that do not exist in the main meta-analysis (30, 31). Results Included studies Figure 1 showed the flowchart of this meta-analysis. After preliminary screening of titles and abstracts, a total of 104 articles (54 ALFF-related and 50 CBF-related) met the requirements. After reading the full text, 37 data sets of 31 studies were included, including 25 data sets for 23 ALFF-related studies and 12 data sets for 8 CBF-related studies. The quality score of the included study met the standard (Supplementary Tables S2, S3, S5). Flow diagram for identifying studies to be included in the meta-analysis. Sample characteristics Of the 23 original ALFF studies, 25 data sets reported the ALFF differences between 801 PD patients (457 males, 344 females, mean age = 60.3 years) and 738 healthy controls (382 males, 356 females, mean age = 59.8 years). Detailed demographic information, clinical features and imaging features were shown in Table 1 and Supplementary Table S6. After analyzing the extracted demographic and clinical information, we found that there were differences in gender distribution (χ2=4.338, p = 0.037), cognitive assessment scales MOCA (standardized mean difference [SMD] = −1.49; 95% confidence interval [CI] = [−1.91, −1.07], Z = 6.95, P < 0.00001), and MMSE (SMD = −0.49; 95% CI = [−0.66, −0.31], Z = 5.44, P < 0.00001) between the two groups. There was no difference between the two groups in terms of age (SMD = 0.57; 95% CI = [−0.18, 1.32], Z = 1.48, p = 0.14) and years of education (SMD = 0.33; 95% CI = [−0.28, 0.93], Z = 1.05, p = 0.29). Table 1Demographic and clinical characteristics of PD patients and HCs included in the meta-analysis of studies on ALFF.StudyIndicatorSubjects (male/female)Mean age (SD)H-Y stageUPDRS III scoreDuration years (SD)MMSE (SD)Education years (SD)MoCA (SD)PDHCPDHCPDHCPDHCPDHCHarrington et al. (32)ALFF31(22/9)30(11/19)67.4(7.5)68.6(7.2)/38.1(14.6)a5.4(3.8)29.3(0.9)29.5(0.7)17.0(2.3)16.5(1.8)//Hou et al. (33)ALFF101(59/42)102(60/42)59.8(7.2)59.9(7.1)1.9(0.7)25.5(11.5)a7.2(4.4)28.7(1.3)29.0(1.1)////Kwak et al. (34)ALFF24(22/2)24(19/5)64.3(8.0)63.3(7.0)2.2(0.3)18.5(8.0)a5.4(3.0)28.8(1.0)29.1(1.0)//26.0(3.0)25.7(3.0)Li et al. (35)ALFF16(6/10)19(11/8)62.8(6.6)62.7(8.1)2.2(0.8)22.1(12.5)4.0(4.3)27.6(2.4)/////Luo et al. (36)ALFF37(17/20)13(6/7)61.5(9.5)62.5(9.6)/38.2(14.9)/26.8(2.9)28.1(1.8)//24.1(4.6)28.8(1.1)Luo et al. (37)ALFF30(15/15)30(15/15)53.6(10.2)51.9(7.7)1.7(0.6)26.8(12.4)2.1(1.3)27.0(2.8)28.1(1.8)////Mi et al. (38)ALFF31(20/11)32(17/15)58.0(9.8)58.3(7.3)1.9(0.6)30.8(14.4)5.2(3.5)27.8(1.7)28.6(1.4)//24.8(3.0)26.2(3.4)Rong et al. (39)ALFF42(26/16)33(17/16)64.5(6.7)63.3(5.3)2.0(0.5)31.2(13.2)2.9(2.2)28.2(1.9)28.6(1.5)10.8(3.3)11.4(3.2)23.3(3.3)26.2(1.9)Skidmore et al. (40)ALFF14(11/3)15(9/6)62.0(9.0)65.0(13.0)/37.0(13.0)/27.0(3.0)28.0(3.0)//25.0(3.0)27.0(3.0)Sun et al. (41)ALFF26(14/12)23(13/10)59.6(10.0)59.5(10.8)1.9(0.6)17.1(3.7)2.0(0.9)25.9(4.3)25.6(4.4)7.1(5.1)7.9(6.0)24.0(5.4)23.6(6.3)Tang et al. (42)ALFF51(27/24)50(21/29)53.2(11.0)51.5(10.7)2.4(0.8)48.6(23.4)a5.8(5.0)27.1(3.6)27.8(3.2)//22.4(5.7)25.2(5.0)Wang et al. (43)ALFF17(9/8)25(14/11)62.5(10.2)64.7(5.2)2.4(0.6)48.4(13.9)6.5(3.6)24.8(4.2)28.5(1.5)10.8(4.2)11.5(3.0)19.7(5.8)26.2(1.4)Wang et al. (44)ALFF33(24/9)19(10/9)69.5(6.0)66.2(3.5)2.4(0.6)22.7(10.8)4.4(3.0)28.1(1.7)28.8(1.0)11.5(4.0)10.6(3.2)//Wang et al. (45)ALFF10(5/5)13(11/2)64.7(7.0)62.9(9.0)1.5(0.5)29.3(9.6)a5.4(7.9)////24.6(2.4)27.9(1.1)Wang et al. (45)ALFF19(14/5)13(11/2)59.1(12.3)62.9(9.0)1.3(0.5)25.7(11.8)a9.5(10.8)////28.4(1.3)27.9(1.1)Wen et al. (46)ALFF16(8/8)21(13/8)60.7(18.7)55.4(16.4)1.6(1.0)33.8(24.2)5.6(7.4)29.2(2.2)/////Xiang et al. (47)ALFF24(12/12)22(11/11)62.7(7.4)65.6(6.9)2.2(0.9)22.0(7.0)7.0(3.3)27.3(2.1)28.6(1.6)13.6(3.1)12.9(3.7)25.9(3.7)25.4(2.5)Xu et al. (48)ALFF19(11/8)32(13/19)60.3(11.3)63.2(4.7)1.4(0.5)26.9(13.5)3.2(3.3)27.1(1.9)28.7(1.3)11.2(4.8)9.8(3.8)//Yao et al. (49)ALFF12(4/8)14(6/8)63.4(7.4)64.1(4.0)2.8(0.9)18.0(12.9)8.4(5.1)28.5(1.7)29.1(0.7)////Yue et al. (50)ALFF26(16/10)10(3/7)60.8(3.5)58.0(4.1)1.4(0.6)33.7(14.0)1.8(1.2)25.9(3.6)27.9(1.3)//22.0(4.2)26.5(3.2)Yue et al. (50)ALFF14(8/6)10(5/5)49.8(3.6)49.7(2.3)1.7(0.6)34.7(10.6)2.2(1.4)26.4(4.4)26.4(2.7)//24.4(4.4)24.6(3.7)Zhang et al. (51)ALFF28(15/13)28(14/14)59.2(9.7)58.2(6.5)2.0(0.7)29.1(8.7)8.5(2.9)27.6(1.3)27.7(1.2)//24.4(2.5)25.9(1.7)Zhang et al. (52)ALFF82(35/47)77(31/46)59.7(11.9)58.6(8.5)/20.2(8.4)7.1(6.0)//////Zhang et al. (53)ALFF32(22/10)25(12/13)65(8.4)64.6(4.5)2.2(0.7)21.6(10.0)4.0(4.0)28.3(1.8)/11.4(3.5)10.7(2.9)//Zhang et al. (54)ALFF66(35/31)58(29/29)53.8(10.7)51.7(10.8)2.3(0.8)30.7(15.3)/26.8(3.7)27.9(3.3)////Data are presented as mean (SD). PD, Parkinson’s disease; HCs, healthy controls; SD, standard deviation; H-Y stage, Hoehn-Yahr stage; UPDRS III score, unified Parkinson’s disease rating scale III score, MMSE, mini-mental state examination; MoCA, montreal cognitive assessment.aOnly UPDRS total scores was given in the study./ means no relevant information was provided in the study. Demographic and clinical characteristics of PD patients and HCs included in the meta-analysis of studies on ALFF. Data are presented as mean (SD). PD, Parkinson’s disease; HCs, healthy controls; SD, standard deviation; H-Y stage, Hoehn-Yahr stage; UPDRS III score, unified Parkinson’s disease rating scale III score, MMSE, mini-mental state examination; MoCA, montreal cognitive assessment. aOnly UPDRS total scores was given in the study. / means no relevant information was provided in the study. A total of 12 data sets were obtained from the 8 studies on CBF, which included 285 PD patients (155 males, 130 females, mean age = 62.3 years) and 302 healthy controls (154 males, 148 females, mean age = 60.4 years). Detailed demographic information, clinical features and imaging features were shown in Table 2 and Supplementary Table S7. After analyzing the extracted demographic and clinical information, we found that there were differences in age distribution (SMD = -1.56; 95% CI = [0.38, 2.75], Z = 2.59, p = 0.01), cognitive assessment scales MOCA (SMD = -2.54; 95% CI = [−3.10, −1.98], Z = 8.85, P<0.00001), and MMSE (SMD = -2.48; 95% CI = [−2.81, −2.16], Z = 15.05, P<0.00001) between the two groups. There was no difference between the two groups in terms of gender (χ2 = 0.677, p = 0.411) and years of education (SMD = −0.46; 95% CI = [−0.98, 0.07], Z = 1.71, p = 0.09). Table 2Demographic and clinical characteristics of PD patients and HCs included in the meta-analysis of studies on CBF.StudyIndicatorSubjects (male/female)Mean age (SD)H-Y stageUPDRS III scoreDuration years (SD)MMSE (SD)Education years (SD)MoCA (SD)PDHCPDHCPDHCPDHCPDHCArslan et al. (55)CBF26(16/10)15(11/4)60.2(9.0)58.7(6.3)1.8(0.5)26.0(10.8)5.4(3.0)29.4(0.8)30.0(0.0)10.1(3.8)11.0(3.8)26.7(1.9)25.2(2.3)Arslan et al. (55)CBF27(21/6)15(11/4)64.0(8.1)58.7(6.3)1.9(0.6)32.4(13.1)6.6(3.5)28.2(1.4)30.0(0.0)9.0(3.8)11.0(3.8)22.4(2.5)25.2(2.3)Barzgari et al. (56)CBF30(24/6)31(25/6)66.1(9.0)67.5(8.3)1.8(0.7)20.3(10.6)6.1(3.9)//////Jia et al. (57)CBF27(15/12)25(11/14)63.1(6.6)59.4(5.8)1.9(0.5)23.8(7.4)3.7(3.0)//13.4(2.9)12.1(2.9)//Jia et al. (57)CBF27(16/11)25(11/14)62.6(6.6)59.4(5.8)1.7(0.7)21.4(9.5)3.7(2.9)//7.8(2.9)12.1(2.9)//Lin et al. (58)CBF20(6/14)22(7/15)63.3(6.4)59.9(6.0)2.0(0.8)22.9(15.1)2.5(1.5)22.6(7.4)27.1(2.1)8.8(4.9)11.5(4.9)//Lin et al. (59)CBF17(6/11)17(8/9)63.7(8.5)59.7(7.5)2.0(2.0)19a3.5(2.4)21.5(4.7)28.7(2.0)7.1(6.0)10.2(6.0)//Lin et al. (59)CBF17(7/10)17(8/9)60.9(10.2)59.7(7.5)2.0(2.0)17a2.5(1.5)28.3(2.3)28.7(2.0)9.3(6.0)10.2(6.0)//Shang et al. (60)CBF42(18/24)50(25/25)66.8(8.4)68.2(4.1)1.8(0.9)42.4(14.2)2.2(1.0)25.2(0.7)28.3(1.2)13.3(2.2)13.2(2.2)22.0(1.9)28.3(1.4)Suo et al. (61)CBF22(9/13)36(15/21)53.8(8.5)53.7(7.3)1.9(0.6)23.2(10.2)2.4(1.7)27.6(2.1)28.2(1.6)10.3(2.9)10.8(2.9)19.1(2.9)23.1(2.5)Suo et al. (61)CBF17(10/7)36(15/21)54.0(8.2)53.7(7.3)1.8(0.6)17.1(9.7)2.2(1.6)27.8(4.4)28.2(1.6)11.3(2.9)10.8(2.9)24.3(2.4)23.1(2.5)Zhao et al. (62)CBF13(7/6)13(7/6)61.9(9.2)62.3(8.1)1.4(0.5)14.2(3.9)3.8(2.9)28.6(1.9)28.8(1.1)11.2(5.6)13.0(5.6)//Data are presented as mean (SD). PD, Parkinson’s disease; HCs, healthy controls; SD, standard deviation; H-Y stage, Hoehn-Yahr stage; UPDRS III score, unified Parkinson’s disease rating scale III score; MMSE, mini-mental state examination; MoCA, montreal cognitive assessment.aOnly the mean value of the data was given in the study./ means no relevant information was provided in the study. Demographic and clinical characteristics of PD patients and HCs included in the meta-analysis of studies on CBF. Data are presented as mean (SD). PD, Parkinson’s disease; HCs, healthy controls; SD, standard deviation; H-Y stage, Hoehn-Yahr stage; UPDRS III score, unified Parkinson’s disease rating scale III score; MMSE, mini-mental state examination; MoCA, montreal cognitive assessment. aOnly the mean value of the data was given in the study. / means no relevant information was provided in the study. Meta-analysis of ALFF Compared with HCs, the ALFF of PD patients decreased in the left striatum (BA 48, MNI: −22, 4, 2; SDM-Z = −3.420, p < 0.0005) and the left anterior thalamic projections (BA 25, MNI: −10, 8, 6; SDM-Z = −2.731, p < 0.005) (Figure 2; Table 3). Compared with HCs, there was no area of increased ALFF in PD patients. These regions showed significant between-study heterogeneity, but there was no publication bias. The jackknife analysis results also suggested that they can be reproduced in most combinations. The forest map for assessing heterogeneity and the funnel map for assessing publication bias were shown in Figure 3. Differences in ALFF and CBF between PD and HCs groups. Meta-analyses results regarding. (A) ALFF difference between PD and HCs, (B) CBF difference between PD and HCs. Table 3Differences between PD patients and HCs.Brain areasMNI coordinateSDM-Zp-valueVoxelsBreakdown (voxels)Egger’s test (p value)Heterogeneity (I2)Jackknife analysisPD